Aptuscan is a privately owned UK biotechnology company founded in May 2008 and supported by MRC Technology and IP Group.
The company’s core technology was developed by Dr Paul Ko Ferrigno and his research team at the MRC Cancer Cell Unit in Cambridge and at the University of Leeds. In 2010, to coincide with further investment, the intellectual property rights covering the core Scannin technology were exclusively licensed to Aptuscan.
As at 30 June 2011 |
IP Group holding |
|
47.8% |
|
Holding represents undiluted beneficial equity interest excluding debt